Get started

Healthcare

Biogen Earnings Swing July 2018Biogen's (344.10 at close at the date of this writing) and Eisai's recent success with BAN24O1, an experimental medication for Alzheimer's which is currently in mid-stage clinical trials, in addition to a recent price target raise by Citi, and overall bullish analyst sentiment led to a rally between July 6-9, 2018. Although the clinical trial's success was certainly reason for bullish sentiment, it ran too far too fast and indicators pointed towards to a sell off. I thus opened put options on July 9, expiring July 13 2018 (currently in the money). We are now only about two weeks away from Biogen's earning report. After studying historical data and charts, I've found that there is often a sell off prior to earnings OR there is a run up then a slight sell off right before the earnings date. I've annotated the chart with periods that indicate this. In this case, I believe downward momentum will continue followed by a slight rally pre-earnings then a sell off. Opening JUL20 puts may be a smart move at this time. In the long term, Biogen -0.21% is very scalable and overall is very promising. I agree with Citi's PT of 371. www.wsj.com
NASDAQ:BIIBShort
by UnknownUnicorn2997486
ASX:PGC Paragon Healthcare - waiting for a good entry pointASX:PGC Paragon Healthcare seems to be gaining traction and has a slight pull back recently but I would still wait for a clearer signal to enter. A nice cup and handle has been formed and i am waiting for the RSI to cross the 50 mark with conviction before entering. That will also mean I prefer to enter after the prices cross back into the main channel at $0.855 at least. It might be proven to be a little late in future but a stronger signal to enter is still a safer bet. If you decide to enter now, set your stop loss tight at $0.795 or $0.765 depending on your risk appetite. Target set at between $0.96 to $1.045 (ATH). A break below $0.765 will invalidate this view.
ASX:PGC
by paper_value
GlaxoSmithKline ShortShort from $42.01. - Market Cap: $102B - Beta: 0.83 - P/B: 20.42 - GSK’s consumer healthcare segment sales were down in 2017 due to a slowdown in global growth of its key consumer categories. - They have also faced pricing pressure from competition and slow down in emerging markets. Although GSK have several candidates in different stages of development, the company has been set back on numerous occasions by the regulators. The largest setbacks in the past few quarters include the phase 3 data on chronic coronary heart disease, Duchenne muscular dystrophy candidate, kydrisa failing to meet the primary end point in a phase 3 study. - The company phases massive competition from small start-ups to large pharmaceutical corporations. There consumer healthcare segment faces competition from big companies like Johnson & Johnson, Colgate Palmolive, Procter & Gamble and Pfizer. - Advair, one of GSK’s largest revenue providers is facing intense competition in the asthma and COPD market from AstraZeneca and Merck respiratory drugs. NeroTree Capital rates GlaxoSmithKline PLC as a SELL with a price target of $38.
NYSE:GSKShort
by UnknownUnicorn2415222
1
SGYP Is Setting Up for A Big Move!SGYP seems to be setting up for a big big move. The Squeeze Momentum Indicator has been forming a triangle which is now about to close and the crosses in the indicator have been black for some time meaning that a release of the squeeze should be about to manifest. My guess is that spike will be to the upside, and it could go as high as 3.60$ (90%+ appreciation), which is the 0.382 retracement level of 17's highs and the 1.618 retracement level of this year's highs.
SLong
by ArthaVidya
1
Fitbit: an AI and IoT Play - This is the Cheapest it's Gonna GetFitbit's value isn't just in its wearables. It's in its data and cloud connectivity. Fitbit's had a good run with its line of functional, stylish activity trackers and health monitors. Customers can choose between classic trackers, a few smart watches, and even smart headphones and weight scales - with a large selection of accessories to mix and match throughout the product line. But that's only taken Fitbit so far - in the case of its stock price, down massively into the single digits since 2016. Fitbit's stock has been adrift in the single-digit doldrums for a long time now. But believe it or not. . . This is the cheapest Fitbit is ever going to get. Why? Because Fitbit is making its foray into its next big space, its next supreme endeavor - health monitoring, big data, electronic medical records, and cloud connectivity. On 4/30/18 Fitbit announced it is partnering with Google's Cloud Platform to facilitate its entry into the data and I.o.T (Internet of Things) of healthcare. Real-time biometrics, new and innovative application use and creation, population health analysis, and more will form the meat-and-potatoes of Fitbit Health Solutions - Fitbit's initiative to use omnipresent real-time and stored data and analysis to achieve positive health outcomes with mass health monitoring. Visionaries and forward-thinkers have been talking about the burgeoning field of biometric sensors and health monitoring for a few years now. Fitbit and Google look to be the mainstream facilitators and operators in this new space of healthcare. And we all know humanity's two concurrent life-changing revolutions - AI and blockchain - will be a big part of this. The technicals are nicely supporting the story. The stock has been in the $5-$6 USD range throughout 2018, and a case could be made for an inverse head-and-shoulders bottom printing since February 2018 to today (though it might be just range noise); but with volume relatively low, we may only just now be at an inflection point - the big moves and big money are probably a little ways out as Fitbit's brand-new endeavors prove themselves throughout the rest of the year and into the next and beyond. Fitbit could be at a massive discount with huge money to be made longer-term. Please like, follow, and share, and maybe we can have fun and do great things together. Thanks again! See it on the site: holsturr.com/category/markets/charts/ ** For speculative and research purposes only - good luck! **
FLong
by holsturr
1
MRK - Too Good To Be True?The price here has focused into the obvious descending triangle for almost about a year now! It is not obvious if it will hold or not, but the current company health especially regarding profitability along with price action point towards a downward move, especially after the bullish momentum over the last couple of days. This play is being taken to play on the chance that the stock continues to retrace some of its gains from the past week, ideally before the next earnings report. Let's see how it goes down; it should be a very short-term trade. Stop @ 60.13 Target @ 57.09
NYSE:MRKShort
by themdtrader
2
UNH - Slowing Down or Beginning of The End?This stock has been one of the best winners in healthcare over the past few years, in terms of company health, profitability and correlation to stock price action. All the same, just like with A , the current market uncertainty has left the stock here in a wedge pattern after its earnings report. Even though the earnings beat estimates, it was not better than the prior growth experienced and so combined with the overbought nature of the stock, this could be a sign that the stock is topping out at least for now. In short, if the company fails to keep growing, fear could set in and investors will go ahead to ease off the gas pedal, leading to a possible bearish trend. For now, I am looking for a bearish drift after earnings, but I look to stay longer if a bearish trend develops; losses will be cut quickly. Stop @ 242.18 Target @ 227.79
NYSE:UNHShort
by themdtrader
PG.... Sad Story but meeting support? I don't follow this stock and it was a friend of mine who pointed it out to me. There is a massive amount of pain in this stock chart. First off, you had a bad, bad break of the 200 day moving average all the way back on January 23rd. If you were watching the charts, this should have been a pretty good signal that something was up with the stock. You also had above average volume coming in confirming that this move was most likely meaningful. The second warning shot was the death cross that happened on February 8th. Today's bloodbath on top of the recent months of selling has taken this puppy all the way back to the levels it was at in January 2016. Ouch If you take this all the way back to 2009 and draw a best fit line, today's prices stopped to meet this trendline support. I would have to hope that the pain is in the past for PG and maybe this is a capitulation "wash out." If it breaks this line.... then "adios amigo." How far it goes, how long it lasts.... nobody knows.
NYSE:PG
by themuzzman
SEVERAL BULLISH SIGNS FOR CHEAP HEALTHCARE STOCKFound myself looking around for some side plays with the stock markets rallying today all while cryptos are facing some uncertainty. I'm also keeping my fingers crossed for UofL to sign Chris Mack as their head men's basketball coach. Anywho lets get into it TRXC TransEnterix is a small healthcare instrument supply company, the fundamentals are not great but its starting to show some great signs, with it appearing to be - breaking out of a down trend from October - printing a cup and handle formation since February - breaking out of a smaller descending wedge for March - SMA 20 crossed above the SMA 50 Given all the factors I'm hoping we can gather support through the .23 retracement and eventually work its way back to the .618 Overall this seems like a cheap play and could be fun to watch over the coming weeks. Not advice - happy Monday *Delgado*
TLong
by aledelga
CHFS CHF-Solutions ER Report WILL IT FILL THE GAP? This needs volume to fill the gap. Not Much news out. Think or swim Calendar says ER is the 15th of March Meeting with investors is on the 18th, saw a decent Roth Conference Slideshow, and they just had an inducement grant approved and I believe there was insider stock purchase a month or two ago. The company will meet with investors throughout the day on Tuesday, March 13, 2018 at The Ritz Carlton, Laguna Niguel, Orange County, Ca. John L. Erb is CEO...Please do your DD but my opinion is this thing has a nice POP coming. Please give any feedback. Good or Bad. Market Capitalization $6.44M $12.97B 9th Total Return (1 Year Annualized) AS OF 03/08/2018 -95.35 24.64 -- Beta (1 Year Annualized) 0.63 0.97 91st EPS (TTM) AS OF 09/30/2017 $-115.40 $0.56 2nd Current Consensus EPS Estimate $-1.26 -- -- EPS Growth (TTM vs. Prior TTM) +79.32% +10.48% 88th P/E (TTM) AS OF 03/09/2018 NM 74.14 -- Dividend Yield (Annualized) -- -- -- Total Revenue (TTM) AS OF 09/30/2017 $3.47M $12.85B 29th Revenue Growth (TTM vs Prior TTM) +538.67% +17.36% 100th Shares Outstanding 1,799,000 649,075,968 3rd Institutional Ownership 26.40% 81.26% 39th
C
by nobodee
1
INSY Target $23 FDA Cannabidiol Fast trackFDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder characterized by insatiable appetite in children that often leads to obesity and type 2 diabetes. “FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, a debilitating condition which currently does not have any approved products available,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. “We plan to start the clinical development program for this promising therapy in late first quarter of 2018.” The most common known genetic cause of life-threatening obesity in children, Prader-Willi syndrome has a prevalence of approximately 1 in 15,000, according to the Prader-Willi Syndrome Association, occurring in males and females equally and in all races. “We are very encouraged by the FDA’s decision to put CBD for Prader-Willi on the Fast Track and believe it is good news for these young patients, their families and clinicians,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “This special regulatory designation represents a significant milestone in the company’s R&D program, which is focused on developing and delivering safe, effective and novel treatment options using cannabinoids and novel drug delivery technology for unmet medical needs.” About INSYS INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. Forward-Looking Statements This news release contains forward-looking statements including regarding (i) our belief that FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, (ii) our belief that Prader-Willi syndrome currently does not have any approved products available and that our proprietary CBD formulation has potential to be a viable treatment option and (iii) our plan to start the clinical development program for this promising therapy in late first quarter of 2018. These forward-looking statements are based on management’s expectations and assumptions as of the date of this news release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to, risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2016 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this news release, and we undertake no obligation to publicly update or revise these statements, except as may be required by law.
ILong
by StockPicksNYC98
October 26 Earnings: Gilead - Flying the KiteGilead's core product pipeline, including recent FDA approval is set to soar as key drugs and generics are continuing to outperform. The company's recent acquisition of KITE Pharma came at the perfect moment with KITE being granted a key drug approval by the FDA. Gilead's recent cost cutting efforts and R&D focus are to further push growth prospect and boost overall FY guidance. Generic competition will continue to weigh, however, and limit some blockbuster drug expansion. I'm starting Gilead with a $90 PT for an extended post-earnings move. A S/L at $75 around recent area is advised.
NASDAQ:GILDLong
by TraderDanER
CVS, waiting for the breakoutThe stock is moving in a sideways parallel channel started at the beginning of 2017. This movement can be a redistribution or an accumulation phase, it depends if it breaks lower or higher. If the price breaks lower the minimum target is around 70 and if it breaks higher the minimum target is around 88. The breakout must be confirmed by very high volume to avoid fakeouts or pullbacks. The informations and the strategies discussed are NOT recommendation to buy, sell or trade any securities. They are strictly for educational and illustrative purposes.
NYSE:CVS
by UnknownUnicorn1249598
PTOY LONG HODL Get it while it's hot!This company is going places, I have been researching the team, the fundamentals, and TA for about a week or two for a few hours every day. The entirety of the staff checks out and they have built a HIPPA approved platform to interface with EMR companies. This will revolutionize healthcare as we know it, they have a free app coming out this month for patients to interface with their care team as well as other individuals with similar conditions. They have been chosen to present at a convention in Atlanta October 2017, have been picked multiple times in multiple places one of the top ten most influential companies, not even at events solely restricted to the crypto space...top ten out of hundreds of other companies. This will disrupt healthcare IT as we know it! They are also doing a trial at 8 hospitals for ninety days. This will climb throughout that time and if even one of those 8 hospitals signs on after the 90 day trial that will send it flying. I have connections in the healthcare space, (specifically pharmaceuticals and EMR) and I have showed them this company and their plan of action and they agree that it is a winner. Oh did I mention they are HIPPA compliant, yes I did, but that is HUGE. My understanding is that they can interface with current EMR companies as well as having the technology to possibly replace them down the road. My understanding is they are also aligned with Kaiser Permanente which is almost enough right there. If you have a little more time than I have taken already there is a great analysis on medium that I cannot take credit for. medium.com Writing this I feel like a schill but this is far from the truth, I have bought in 3x and plan to as much more as I can, my family is and my friends are. This one is a win that I may not ever let go of.
Long
by Uptrender2ThePhlow
3